Table 3.
Relative power spectra. In stage 2, subjects had greater relative delta and relative theta in the placebo condition, while in both stage 2 and stage 3, subjects had greater relative fast sigma in the zolpidem condition
| Placebo | Zolpidem | ||||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Stage 2 | SWA | 59.11 | 8.68 | 60.54 | 10.7 |
| Delta | 13.98* | 1.96 | 13.55 | 2.32 | |
| Theta | 2.62* | .70 | 2.34 | .676 | |
| Slow sigma | .779 | .371 | .847 | .454 | |
| Fast sigma | 1.42 | .509 | 1.74* | .735 | |
| Stage 3 | SWA | 62.79 | 6.30 | 65.9 | 7.85 |
| Delta | 16.14 | 1.96 | 14.96 | 2.14 | |
| Theta | 1.37 | .417 | 1.24 | .445 | |
| Slow sigma | .295 | .191 | .348 | .294 | |
| Fast sigma | .496 | .229 | .640* | .409 | |
Table represents mean and standard deviation of measurement of relative power across the spectral frequency bands. Asterisks represent significance at p < 0.05